Publications by authors named "Yi-Bing Shao"
Article Synopsis
- Previous research suggested that transfemoral TAVR with self-expanding valves is a safe option for patients with severe aortic regurgitation (AR), but there’s a lack of randomized trial support for this treatment.
- The SEASON-AR trial is a multi-site, randomized study involving 210 high-risk patients, comparing TAVR treatment with guideline-directed medical therapy (GDMT) to GDMT alone, focusing on key outcomes like major adverse cardiac events after 12 months.
- This trial is the first of its kind designed to evaluate the effectiveness and safety of TAVR in high-risk patients with severe pure native AR, potentially paving the way for new treatment protocols.
Objective: To evaluate the feasibility and tolerability of metoprolol standard dosing pathway (MSDP) in Chinese patients with acute coronary syndrome (ACS).
Methods: In this multicenter, prospective, open label, single-arm and interventional study that was conducted from February 2018 to April 2019 in fifteen Chinese hospitals. A total of 998 hospitalized patients aged ≥ 18 years and diagnosed with ACS were included.
Article Synopsis
- Current guidelines recommend 12 months of dual antiplatelet therapy (DAPT) for acute coronary syndrome (ACS) patients after drug-eluting stent (DES) implantation, but recent studies suggest that 3 months of DAPT followed by ticagrelor alone might also be effective and safe.
- The IVUS-ACS and ULTIMATE-DAPT trial aims to compare the safety and effectiveness of IVUS-guided versus angiography-guided DES implantation and to evaluate the impact of ticagrelor monotherapy versus ticagrelor plus aspirin on bleeding risks and major adverse cardiovascular events over a year following the procedure.
- The study will involve 3,486 ACS patients who
Role of Jagged1-Hey1 Signal in Angiotensin II-induced Impairment of Myocardial Angiogenesis.
Chin Med J (Engl)
February 2017
Article Synopsis
- * The study investigated how Jagged1-Notch signaling is affected by Ang II in the context of this impaired angiogenesis and cardiac hypertrophy using male mice and specific treatments.
- * Results indicated that Ang II caused significant cardiac hypertrophy and reduced angiogenesis, while the protein Jagged1 increased but its gene expression decreased in the heart tissue, suggesting a complex interaction in the disease process.